

Megan Melody

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3316489/publications.pdf>

Version: 2024-02-01

13
papers

56
citations

2258059

3
h-index

1720034

7
g-index

13
all docs

13
docs citations

13
times ranked

92
citing authors

#	ARTICLE	IF	CITATIONS
1	Treatment outcomes for patients with myelodysplastic syndrome/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis. <i>Leukemia and Lymphoma</i> , 2022, 63, 199-204.	1.3	3
2	Incidence of thrombosis in relapsed/refractory B-cell lymphoma treated with axicabtagene ciloleucel: Mayo Clinic experience. <i>Leukemia and Lymphoma</i> , 2022, 63, 1363-1368.	1.3	4
3	C-reactive protein and ferritin levels and length of intensive care unit stay in patients with B-cell lymphomas treated with axicabtagene ciloleucel. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2021, 14, 141-146.	0.9	5
4	Impact of hypoalbuminemia on the prognosis of relapsed/refractory B-cell lymphoma treated with axicabtagene ciloleucel. <i>European Journal of Haematology</i> , 2021, 107, 48-53.	2.2	3
5	23-Year-Old Female With Right-Sided Weakness and Aphasia. <i>Mayo Clinic Proceedings</i> , 2021, 96, 1634-1638.	3.0	0
6	Predictors and management of relapse to axicabtagene ciloleucel in patients with aggressive B-cell lymphoma. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2021, , .	0.9	2
7	Defining Acute Myeloid Leukemia Ontogeny in Older Patients. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 312-315.	0.4	5
8	Use of Tocilizumab in Management of Post-Operative Myelomonocytic Leukemoid Reaction. <i>Leukemia Research Reports</i> , 2020, 14, 100228.	0.4	2
9	Follicular lymphoma associated paraneoplastic myositis. <i>Clinical Case Reports (discontinued)</i> , 2020, 8, 2003-2006.	0.5	0
10	Case report: use of lenzilumab and tocilizumab for the treatment of coronavirus disease 2019. <i>Immunotherapy</i> , 2020, 12, 1121-1126.	2.0	18
11	Decoding Bone Marrow Fibrosis in Myelodysplastic Syndromes. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 324-328.	0.4	13
12	Baseline Hypoalbuminemia Does Not Appear to be an Adverse Prognostic Factor in Patients with Relapse/Refractory B-Cell Lymphomas Treated with Axicabtagene Ciloleucel (axi-cel). <i>Blood</i> , 2019, 134, 5343-5343.	1.4	1
13	Impact of Anti-CD19 CAR-T Axicabtagene Ciloleucel on Vaccine Titers of DTaP and MMR. <i>Blood</i> , 2019, 134, 5610-5610.	1.4	0